HCM
OCUL icon

Highbridge Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Highbridge Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,544
Closed -$107K – 1496
2017
Q1 		$107K Buy
+11,544
New +$96.1K ﹤0.01% 1377
2016
Q3 		– Sell
-22,354
Closed -$111K – 1583
2016
Q2 		$111K Buy
+22,354
New +$221K ﹤0.01% 1301

Other funds holding OCUL

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's OCUL Position: Q2 2017 in Review

Highbridge Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2017, closing a stake of 11,544 shares — an estimated $107K sold.

Highbridge Capital Management first reported a position in OCUL in Q2 2016 and held it in 2 quarters. The position peaked at $111K in Q2 2016. 72 funds tracked by Wall St. Rank hold OCUL as of Q2 2017.

  • Highbridge Capital Management reported no remaining Ocular Therapeutix position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 11,544 Ocular Therapeutix shares in Q2 2017, an estimated $107K.
  • Highbridge Capital Management first reported a position in Ocular Therapeutix in Q2 2016 and held it in 2 quarters.
  • Highbridge Capital Management's Ocular Therapeutix position peaked at $111K in Q2 2016.
  • 72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.